close

Enter

Log in using OpenID

Acromegaly Treatment Market

embed
Acromegaly is a rare disorder caused due to the excess production of growth hormone by the pituitary gland, affecting a patient’s physical appearance and internal organs.
Acromegaly Treatment Market Exposure to varied markets,
capacity expansion & diversification key triggers Estimated By
Global
Players
Pfizer
Inc.,
Novartis
Pharma
AG,
GlaxoSmithKline plc, Midatech Pharma PLC
Acromegaly is a rare disorder caused due to the excess production of growth hormone by the
pituitary gland, affecting a patient’s physical appearance and internal organs. It is usually
caused by benign pituitary tumor (adenoma), however, in rare cases acromegaly symptoms can
be observed due to ineffective control of growth hormone-secreting cells by hypothalamus.
Abnormal enlargement of hands, arms, feet, legs, and head, and gradual changes in facial
features such as eye-brow, lower jaw, and nose are visible symptoms of this disorder. Untreated
acromegaly leads to serious and life threating complications such as cardiomyopathy and
ventricular arrhythmia. Blood test to measure levels of growth hormones or insulin-like growth
factor and imaging of tumors through MRI scan and CT scan are commonly used diagnostic
approaches to detect acromegaly. Some medications are 90% effective in shrinking tumor,
however, success rate of type of treatment varies based on age, health or medical history of
patients. According to the American Society of Clinical Oncology (ASCO), 14,230 individuals of
the U.S. were diagnosed with pituitary gland tumor in 2017, of which majority are benign
tumor. Furthermore, in 2017, the National Organization for Rare Disorders estimated the
prevalence rate of acromegaly as 50-70 person per million and 3 new cases occurs per million
every year, which is expected to increase the demand for acromegaly treatment market.
Download PDF Brochure Of This Research Report @
https://www.coherentmarketinsights.com/insight/request-pdf/1477
Market Driver:
New drugs in the market widens the choice of therapies for doctors and patients. In 2017,
Midatech Pharma PLC submitted clinical trial application in human study of Q-Octreotide
(MTD201) programme in cancer and acromegaly, and now it has received oral confirmation
from Polish regulators for its approval in January 2018. Furthermore, Chiasma Inc’s new oral
maintenance therapy for acromegaly treatment named Mycapssa, which has completed an
international Phase 3 trial and further conducting an international Phase 3 clinical trial under a
protocol accepted by the European Medicines Agency (EMA) for adult patients with acromegaly
is also expected to boost growth of acromegaly treatment market over the forecast period.
Expiration of drug patents during the forecast period can hamper the market temporarily.
As acromegaly is a non-preventable disease, early detection of the disease will help to cure the
disease symptoms. Increasing awareness to differentiate between acromegaly and other disorders
like gigantism, Marfan syndrome, and Pachydermoperiostosis, and further detecting the
symptoms and diagnosing it will help in propelling the acromegaly treatment market growth.
For instance, Acromegaly Awareness Day was celebrated on November 1, 2017 for the first time
by World Alliance of Pituitary Organization (WAPO) and Pituitary Network Association to
increase awareness on diagnosing the symptoms of this disease without any delay. Some
foundation provided financial assistance to medicare patients suffering with acromegaly. For
instance, in December 2017, HealthWell Foundation launched a new fund scheme where it
provided a fund of US$ 10,000 for a 12-month grant to acromegaly patients who have annual
household incomes up to 400 percent of the federal poverty level. Such funding programs will
provide financial ease to the patients suffering from acromegaly, which in turn will propel
growth of acromegaly treatment market. In 2017, Crinetics Pharmaceuticals, Inc. was awarded
Phase IIB Small Business Innovation Research (SBIR) grant of up to US$ 2.8 million from
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National
Institutes of Health (NIH) for the development of company’s orally-available, non-peptide
somatostatin agonist drug candidate, CRN00808 that can be used for the treatment of
acromegaly.
Report includes chapters which deeply display the following deliverable about industry :
• Acromegaly Treatment Market Research Objective and Assumption
• Acromegaly Treatment Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Acromegaly Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Acromegaly Treatment Market, By Regions
• Acromegaly Treatment Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Acromegaly Treatment Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Acromegaly Treatment Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Acromegaly Treatment Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Acromegaly Treatment Market – Competitors:
Pfizer Inc., Novartis Pharma AG,
Biopharma plc, Chiasma Inc, Aegis
Ltd, Crinetics Pharmaceuticals Inc,
Inc. are the major players involved
GlaxoSmithKline plc, Midatech Pharma PLC, Strongbridge
Therapeutics LLC, Amryt Pharma plc, Antisense Therapeutics
Dauntless Pharmaceuticals Inc, and Ipsen Biopharmaceuticals
in acromegaly treatment market.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/acromegaly-treatment-market-1477
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars,
called PHASE-XS. This database provides analytical data in addition to the clinical information
of ongoing trials for biologics and biosimilars. An amalgamation of more than 30 parameters,
PHASE-XS helps biotechnology and pharmaceutical companies to analyze the market trend,
competition, and market potential. For more information or to access this database, kindly click
on the below link or contact at [email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
1/--pages
Report inappropriate content